Drugs / CD19+ feeding T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03984968 | Jul 2017 → Jul 2025 overdue | B-cell adult acute lymphocytic leukemia | The First Affiliated Hospital of Soochow University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19+ feeding T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03984968 ↗ |
| Known as | FTCs | “CD19+ feeding T cells (FTCs) infusion” NCT03984968 ↗ |
| Modality | Cell therapy | “autologous T cells engineered to express CD19, namely CD19+ feeding T cells (FTCs)” NCT03984968 ↗ |